

From: [Jason Xu](#)
To: [Trials](#)
Cc: [Mark Nielsen](#); [Wook Pak](#); [HuaChen SBPA](#); [John Handy](#)
Subject: IPR 2025-01593 Bonerge Lifescience (Hunan) Co., Ltd. v. Nanjing Nutrabuilding Bio-Tech Co., Ltd.- Stipulation
Date: Thursday, October 23, 2025 10:15:44 AM

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

To the Honorable Board,

Bonerge Lifescience (Hunan) Co., Ltd. (“Bonerge”) has provided to following stipulation in connection with the IPR petition 2025-01593 (“Petition”) it filed to Nanjing Nutrabuilding Bio-Tech Co., Ltd..

Bonerge hereby stipulates that, should the PTAB institute review of the Petition, it would not pursue in the district court litigation (Case No. 25–cv–00271, filed in C. D. Cal.) any grounds that are raised or reasonably could have been raised in the IPR. Bonerge hereby further stipulates that, should IPR2025-01593 be instituted, it would not pursue in the district court litigation any invalidity grounds under 35 U.S.C. §§ 102 and 103 against the ’961 Patent—including those grounds with system prior art. For the sake of clarity and to avoid any doubt, if the PTAB declines to institute IPR2025-01593, Bonerge reserves the right to assert any grounds of invalidity in the district court litigation against the ’961 Patent.

Best regards,
Jason

Jason Xu | Partner

RIMÔN LAW

+1 202-470-2141 | jason.xu@rimonlaw.com | [bio](#)

1050 Connecticut Ave, NW Washington DC 20036
Suite 500

www.rimonlaw.com | [See Our 30 International Offices](#) | [Read Our Insights](#)

Follow us on [Twitter](#) | [Connect on LinkedIn](#) | Like us on [Facebook](#)